Topical immune response modifiers: Adjuvants

Annemarie Uliasz, Mark Lebwohl

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The topical immune response modifier imiquimod is a low molecular weight heterocycline imidazoquinoline amine. Imiquimod stimulates both the innate and the acquired arms of the immune system via induction of T-helper-1 cytokines Imiquimod is Food and Drug Administration approved for the treatment of anogenital warts, but is widely used to treat other warts and molluscum contagiosum. Nonantiviral uses of imiquimod include actinic keratoses and superficial basal cell carcinomas.

Original languageEnglish
Title of host publicationClinical and Basic Immunodermatology
PublisherSpringer London
Number of pages11
ISBN (Print)9781848001640
StatePublished - 2008


Dive into the research topics of 'Topical immune response modifiers: Adjuvants'. Together they form a unique fingerprint.

Cite this